<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02073019</url>
  </required_header>
  <id_info>
    <org_study_id>BL-8040.02</org_study_id>
    <nct_id>NCT02073019</nct_id>
  </id_info>
  <brief_title>A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Two Part Study Exploring the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effect of Ascending Doses of BL-8040 in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLineRx, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLineRx, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether BL-8040 is safe, tolerable and effective in&#xD;
      the mobilization of Hematopoietic Stem Cells (HSC) in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with Adverse Events</measure>
    <time_frame>Up to 7 days after treatment comletion</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BL-8040</intervention_name>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects&#xD;
&#xD;
          -  BMI between 18 and 30 kg/m2 and Weight â‰¥ 60 Kg&#xD;
&#xD;
          -  Subjects must be either surgically sterilized (vasectomy), or if their partner is of&#xD;
             childbearing potential, must use two methods of contraception, one of which must be a&#xD;
             barrier method, from the first dose until 3 months after the last dose&#xD;
&#xD;
          -  Subject is able and willing to comply with the requirements of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant disease&#xD;
&#xD;
          -  Any illness within the 4 weeks prior to the screening examination&#xD;
&#xD;
          -  Any history of alcohol and/or drug of abuse addiction and/or active / past (up to 2&#xD;
             years before screening) nicotine consumption&#xD;
&#xD;
          -  Clinically relevant deviation from normal in the physical examination and vital signs&#xD;
             at screening or baseline&#xD;
&#xD;
          -  Clinically relevant laboratory abnormalities identified at screening or baseline&#xD;
&#xD;
          -  Positive tests at screening for HIV I &amp; II, hepatitis B and/or hepatitis C in both&#xD;
             parts or positive tests for Syphilis, HTLV I &amp; II and Nucleic Acid Test (NAT) for HIV&#xD;
             and HBV&#xD;
&#xD;
          -  Positive test for urine drugs of abuse or by anamnesis (Barbiturates, Benzodiazepines,&#xD;
             Amphetamines, Opiates, Cocaine, Cannabinoids, Methadone, Phencyclidine, and Tricyclic&#xD;
             Antidepressants) and/or positive alcohol blood test&#xD;
&#xD;
          -  Subjects who have lost or donated in excess of 400 mL of blood within 3 months prior&#xD;
             to Day 1 of the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Aharon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>BioLineRx, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Clinical Research Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

